J&J Says Icotyde Pill Beat Placebo in Psoriatic Arthritis Trial, 58% to 41%

Johnson & Johnson announced Saturday, Nov. 7, that Icotyde (icotrokinra), its once-daily oral pill, met the primary goal of a Phase 3 trial in psoriatic arthritis. The results were presented as a late-breaking poster at the American College of Rheumatology's ACR Convergence 2026.

The ICONIC-PsA 1 study enrolled 552 biologic-naïve adults with active psoriatic arthritis. Patients got Icotyde 200 mg or a placebo.

The numbers

At Week 16, 58% of patients on Icotyde reached an ACR20 response, meaning at least a 20% improvement in tender and swollen joint counts plus other measures of disease activity. In the placebo group, 41% did.

That is a 17-point gap. The placebo number is not small, and readers should keep it in view when reading the headline figure.

J&J also reported tougher benchmarks:

• ACR50: 29% on Icotyde versus 16% on placebo
• ACR70: 13% versus 5%

J&J described those two results as "numerically higher" and did not attach a significance claim to them. The primary endpoint is the one it says was met with statistical significance.

Skin results

Among patients with qualifying skin involvement, 57% on Icotyde reached clear or almost clear skin (IGA 0/1), compared with 14% on placebo. On the PASI 90 measure, 37% on the drug hit that mark versus 6% on placebo. J&J labeled both comparisons "nominal p<0.001," a designation that is not the same as a pre-specified, multiplicity-adjusted test of the primary endpoint.

J&J's release says the drug showed joint and skin improvements through Week 24.

Safety

J&J said safety findings were consistent with Icotyde's established profile and that no new safety signals were identified. The company did not publish a detailed adverse-event breakdown in its announcement.

Where the drug stands

The FDA approved Icotyde in March for moderate-to-severe plaque psoriasis in patients 12 and older. At that time, additional trials, including this psoriatic arthritis study, were still running. J&J markets the drug with Protagonist Therapeutics.

Icotyde is not approved for psoriatic arthritis. J&J calls it the first and only targeted oral peptide that blocks the IL-23 receptor.

The company's global immunology head, David Lee, said about 30% of patients with psoriasis also have psoriatic arthritis. "Patients don't want to be overtreated, they want a treatment that fits them where they're at," Lee told Reuters.

Joseph F. Merola, who leads the Psoriasis and Psoriatic Arthritis Multicenter Advancement Network and is president of the Rheumatologic Dermatology Society, said the results show potential "to open an entirely new chapter in treating psoriatic arthritis with an oral option." He added that patients "continue to need treatment options that can provide meaningful improvement across both" joint and skin disease. J&J's release identifies Merola as the source of that quote.

The money and the competition

J&J expects peak sales for Icotyde to top $5 billion across multiple indications. Wall Street analysts have tipped the pill as the company's next blockbuster, according to Reuters.

The psoriatic arthritis market is not empty. Injectable biologics such as AbbVie's Skyrizi and UCB's Bimzelx are established. Oral options, including Sotyktu and Otezla, are already on the market.

The pitch for Icotyde is convenience: a daily pill instead of an injection, if regulators approve it for this use. Whether it can pull share from entrenched competitors will depend on data beyond a single trial in patients who had never taken a biologic.

J&J's announcement covered biologic-naïve patients only. The trial does not speak to people who have already tried and failed on biologic drugs.

What comes next

The next step is regulatory. J&J would need to file for a psoriatic arthritis indication and win FDA review before doctors could prescribe Icotyde for the condition. The company's announcement did not give a filing date.